Proteon begins second Phase III trial of vonapanitase for CKD

Proteon Therapeutics has enrolled first patient in the second Phase III clinical study of its investigational product candidate vonapanitase (formerly PRT-201) for chronic kidney disease (CKD).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news